Review

Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists

Baptist Gallwitz

Manuscript submitted December 22, 2009; resubmitted December 27, 2009; accepted December 27, 2009.

Keywords: type 2 diabetes, beta-cell, DPP-4 inhibitors, extrapancreatic effects, incretin, weight loss, glycemia, insulinotropic polypeptide

Abstract

The diverse actions of the incretin hormone glucagon-like peptide (GLP)-1 include insulinotropic, beta-cell preservative, cardioprotective and vasodilatory effects. This spectrum makes GLP-1 an appealing therapeutic option for patients with type 2 diabetes. However, its rapid metabolism by the enzyme dipeptidyl peptidase (DPP)-4 renders it impractical. Incretin-based analogues have been developed to extend endogenous GLP-1 action (GLP-1 receptor agonists) and to hamper its degradation (DPP-4 inhibitors). Evidence suggests that GLP-1 receptor agonists and DPP-4 inhibitors have different pharmacodynamic and pharmacokinetic effects. For example, GLP-1 receptor agonists deliver supraphysiologic levels of GLP-1 analogues designed to resist inactivation by DPP-4, whereas DPP-4 inhibition conserves native GLP-1 resulting in concentrations within the physiologic range. Furthermore, GLP-1 receptor agonists induce glucose-dependent insulin secretion, beta-cell protection, and other extraglycemic benefits such as weight loss and improvement in markers of cardiovascular risk. In contrast, DPP-4 inhibitors are weight neutral and have modest effects on glucose control. DPP-4 inhibition is dependent on the availability of endogenous GLP-1, which appears to be adversely affected by type 2 diabetes and its progression. Therefore, DPP-4 inhibitors may be better suited for patients with mild hyperglycemia without comorbidities. This review examines the present understanding of the pancreatic effects of endogenous GLP-1, and the extrapancreatic actions it exerts on human bodily systems. Also, it analyzes available preclinical and clinical data on incretin therapies with respect to glycemia, lipids, blood pressure, and weight.

Fulltext: HTML , PDF (191KB)

This article has been cited by other articles:

	Exendin-4 attenuates lipopolysaccharides induced inflammatory response but does not protects H9c2 cells from apoptosis Chen TH, Wo HT, Wu CC, Wang JL, Wang CC, Hsieh IC, Kuo CY, Liu CT Immunopharmacol Immunotoxicol 2011. epub
	Role of incretin therapy at various stages of diabetes Cernea S Rev Diabet Stud 2011. 8(3):323-338
	Liraglutide therapy for type 2 diabetes: overcoming unmet needs Sjöholm A Pharmaceuticals 2010. 3(3):764-781